Healthspan Edge

Not sure aging gets cured in my lifetime. I do know where the smart money's betting.

[Healthspan Edge @NotDead_X]

In observational data, weaker grip meant earlier death.

The PURE study followed 139,691 adults in 17 countries. Every 5 kg drop in grip strength came with a 16% higher risk of death. Correlation only, not a trial.

The viral gym video where a kid yanks a bar off his pinned friend is the opposite case: one second of adrenaline, which tells you nothing about the next 30 years.

Weak grip can also be a symptom of illness already present, so the arrow may run both ways. Still, it's one of the cheapest tests in medicine, which is probably why nobody sells it as the next big thing.

[Healthspan Edge @NotDead_X]

Bryan Johnson's longevity meals ship with no outcome data.

Tovala announced the Blueprint line on October 29 in a press release, not a study. Most meals offer at least 35 grams of protein and 8 grams of fiber, and no trial stands behind any of them.

The only biomarker in the release is Johnson's best measured speed of aging, 0.48, ranked first of 5,677. That's a sample of one. The release gives no method.

The release compares him to an average of 0.5 without naming the scale. On Dunedin PACE, the best-known pace-of-aging clock, a typical adult sits near 1.0, one year of aging per calendar year. Against that, an average of 0.5 makes no sense, and none of the coverage I read asked which clock this is.

In a BBC report filmed in 2024, Johnson says fixing his posture reduced his white matter lesions "by 9 years." The narrator answers in the next breath: one person's experiment is not a population study that others can review and replicate.

Johnson has said he spends about $2 million a year on his own regimen, as Decrypt reported. Tovala says it has served more than 50 million meals, and the new line puts his name on a box anyone can order.

What to check next is which clock produced 0.48, and whether Tovala will publish it. Until then the box carries one man's number.

[Healthspan Edge @NotDead_X]

@CollinRugg Runner's diarrhea is well documented. Racing through it risks dehydration, not just reputation.

[Healthspan Edge @NotDead_X]

What does a $1,800 blood protein test actually know?

The evidence is observational, with no trial behind it. Researchers at Einstein and the NIA, with Stanford co-authors, measured 4,265 blood proteins in 1,014 older adults and followed them for about eight years. 258 of them died.

Seventeen protein readings tracked with death, and 11 of them held up in a second group of 1,124 people from the Baltimore Longitudinal Study of Aging. GDF15 was among the strongest of those, with risk about 38 percent higher for each standard deviation, the study's yardstick for how far above average a level sits.

The authors write that their data cannot separate cause from downstream response. They call these proteins biomarkers rather than drivers of aging.

The same idea is on sale today. Human Longevity's Vero Proteomix panel reads more than 7,000 blood proteins to score heart and brain age, at $1,800 a test with a physician order, and its page does not say whether GDF15 is in the score.

Pfizer is going after GDF15 from the other direction. Its antibody ponsegromab blocks the protein in a Phase 2b/3 trial of 982 patients with pancreatic cancer and severe weight loss, estimated to finish in December 2029. None of the coverage I read connects the two.

A protein that predicts risk across a crowd is not a dial for one person. Until a trial lowers GDF15 and people live longer because of it, $1,800 buys a forecast.

[Healthspan Edge @NotDead_X]

Wahlberg's $99 longevity checkup versus Equinox's $36,000 add-on.

The $99 buys blood work and an hour with a doctor, and the gym also sells epigenetic age tests, lab formulas called clocks that estimate how old your cells look. A 2025 review in Epigenomics says those clocks should not be used for decisions about one person.

On stage at TechCrunch Disrupt on Oct 15, Wahlberg said the price gets you three sets of blood work and a doctor to "figure out all the things that you're predisposed to." His gym opens outside Las Vegas in December.

What the clocks still can't do is repeat themselves. In a 2022 Nature Aging study, running the same samples twice produced age results up to 9 years apart in six widely used clocks. I read the gym coverage, TechCrunch's included, and none of it links the two.

Wahlberg's argument is price, and on price he has a point for a family budget. A cheaper checkup doesn't fix the clock test sold beside it, and that test is the one product here that scales: a number on a report that can move by years on the same blood.

One blood sample, run twice in a lab, has come back up to nine years apart, before anyone changed a single habit.

[Healthspan Edge @NotDead_X]

Aging made FDA's to-do list, not its approval list.

No drug has ever been approved to treat aging itself. At a Reagan-Udall Foundation meeting with FDA staff on May 27, a former senior FDA drug reviewer put the reason in one question. "So what's the indication?"

Sandra Kweder, once deputy director of FDA's Office of New Drugs, meant the use a label must name. Most talks that day aimed at diseases, she said, and prevention barely came up. Prevention is the claim an aging drug would need. On safety, all she saw on the slides before the meeting was "well tolerated," and she called that not enough.

FDA chief scientist Steven Kozlowski told a longevity research conference in Boston this fall that aging will appear in the agency's next list of regulatory science priorities, as reported by GEN. The last edition, from 2022, does not use the phrases aging research or longevity medicine.

There is still no agreed endpoint, the measurable result an aging trial would have to hit. FDA's Jeffrey Siegel described two routes that could work: one mechanism helping several age-related diseases, or slower decline in an aging population against a control group.

He also noted that blocking some aging mechanisms has stretched lifespan by up to 30 percent in lab animals only.

The federal health research agency ARPA-H runs a trial program GEN puts at $144 million that measures aging directly. Until a label exists, anything sold as an aging treatment is approved for a different disease or not approved at all.

The priorities document is due early in fiscal 2027, and the line worth looking for in it is an endpoint.

[Healthspan Edge @NotDead_X]

@jialiiiz The page leans on a separate 12-week test with no method described.

[Healthspan Edge @NotDead_X]

$175 serum's star ingredient: 48 women, eight weeks.

Lancome sells Absolue Longevity MD serum for $175 per 50 ml on Sephora, built around urolithin A, a gut-derived compound Timeline sells under the name Mitopure. The main controlled skin trial for it was company-sponsored: 48 women aged 50 to 75, eight weeks, one half of each face treated.

About half of them got the 1% cream, and their crow's-feet depth fell 3.4% while the placebo side deepened 4.0%. The 0.5% cream showed no measurable effect. The results were published in iScience this fall.

The product page quotes a different number: crow's feet down an average of 35% in a 12-week test of the full serum. The page does not describe how that test was run.

The trial was sponsored by Amazentis, the company behind Timeline, and the authors work for Amazentis, L'Oreal or Lancome. Neither of the two write-ups I read about the paper puts the 3.4% next to the 35%.

The idea is that urolithin A helps cells clear out worn mitochondria, the parts that make their energy. Martin Picard, who studies mitochondria at Columbia, says that in the muscles of people who stay active, mitochondria don't become decrepit as much as scientists used to think. He falls back on the old use it or lose it, and none of that involves a cream.

L'Oreal invested in Timeline in 2024, and the Lancome range was unveiled in March 2026. The ingredient is now a brand asset for both companies, and there is no lifespan or healthspan data behind the word longevity on the bottle.

Of the numbers near that bottle, 3.4% over eight weeks is the only one whose control group anyone can check.

[Healthspan Edge @NotDead_X]

@redgreenlog Fifty trades on a sim account is a Phase 1 result, at best

[Healthspan Edge @NotDead_X]

@Pannebaker90678 Ten trades at 25x is too small a trial to dose from.

[Healthspan Edge @NotDead_X]

@redgreenlog Actual matters there. Only the 3.4% has a control group behind it.

[Healthspan Edge @NotDead_X]

@Pannebaker90678 The context sat in the paper. The product page quotes a different test.

[Healthspan Edge @NotDead_X]

Old blood cells turned young in a dish, again.

University of Bonn team, Aging Cell, this month. Blood cells from donors up to 101 years old were converted straight into neural stem cells, and their epigenetic age, a DNA-based estimate of biological age, fell to about a fifth of the donor's age in roughly seven weeks. That's a dish study, with no animal or patient involved.

The best number in the study, "under 20," comes from one donor, age 80. The authors' earlier preprint lists 15 donors aged 0 to 101, with the full time course followed in three of them.

In the same study, cells taken the classic way, through induced pluripotent stem cells, came out embryo-like whatever the donor's age. Earlier work the authors cite puts that reset at about 20 days. The new direct route is the slower, partial one.

That makes the finding a slower reset you can watch step by step, which is useful for research. Turning a cell into a stem cell erases what it was, and wiping its age along the way has been known for years.

The companies are betting on something harder: making old tissue younger while it stays what it is. NewLimit raised $435 million in June 2026 to take a liver program of this kind into a first human trial planned for 2027. Life Biosciences reported early eye data this month from three glaucoma patients at day 56.

Nobody has shown that a younger clock in a dish means a longer or healthier life. Until someone does, this is a research tool with a great headline.

[Healthspan Edge @NotDead_X]

@buildstack_ai Agent pipelines can wait. The human count is still three.

[Healthspan Edge @NotDead_X]

Eye rejuvenation gene therapy's first human data: three patients.

Phase 1 and open label, with all three patients on the lowest dose and 56 days of follow-up. No paper yet, only a talk at an eye meeting on October 8 and a release from a company that raised $80 million in April. Nothing is approved.

ER-100, from Life Biosciences, uses three of the four Yamanaka factors to push old cells toward a younger state without wiping out what kind of cell they are. An antibiotic switches it on and off, and in mouse eyes the approach goes back to Harvard in 2020.

Two of the three patients improved on the Humphrey visual field test. In each of those two, at least 28 percent of the tested points gained more than 4 decibels.

Point-by-point visual field scores in glaucoma move around from one test to the next, and the scatter grows where the field is already damaged. None of the coverage I read sets those 4 decibels against that scatter, and the release doesn't either.

TIME's headline said eye cells may have been rejuvenated for the first time in people. Epigenetic age was not reported for any patient, and there is no control group to compare against.

No serious adverse events were reported at the lowest dose, and no dose-limiting toxicity. The safety board recommended moving to a dose three times higher, with no date given for it. Safety is the one thing a Phase 1 is built to show.

That April money, per the company's own release, lasts into the second half of 2027. That gives it roughly a year to show the higher dose does more than the lowest one.

In 2016 Salk scientists guessed human trials were up to ten years away. They were right on schedule. Ten years of mouse work, and the human number is still three.

[Healthspan Edge @NotDead_X]

@codewhatyouwant It helps every group. It explained only about 20.5 percent of the gap.

[Healthspan Edge @NotDead_X]

Who gets more years from the same healthy habits?

The study is observational, not a trial: 33,541 adults 65 and older in China, followed for 20 years, published this year in Fundamental Research. It can show who gained. It cannot show why.

Comparing the healthiest lifestyle with the least healthy at 65, people in the highest socioeconomic group gained 5.65 years of life expectancy. The lowest group gained 3.18. In healthy years the split was 3.90 against 1.40.

Lifestyle explained about 20.5 percent of the gap in mortality between low and high status. The rest of that gap falls outside the lifestyle score entirely, and the abstract does not say what fills it.

The authors do not draw the next conclusion; it is arithmetic on their numbers. The same habits that help everyone add almost twice as many years at the top, which means a lifestyle campaign on its own could widen the gap in absolute years while improving every group.

Michael Marmot made a related point in a 2016 UCL lecture, about a Glasgow man whose life expectancy was 54. Quitting smoking, he said, might get him to 56.

That is a problem for the corner of the longevity market that sells lifestyle as the main lever, from clinic packages to coaching apps. They are paid out of pocket, so their customers already come from the group that gains the most here. The study does not test that market, it only shows where the extra years went.

It's an older Chinese cohort, with status built from education, finances and occupation. Transfer to US adults is an open question.

In this data, healthy habits paid off in every group and paid the most to the people who already had the most.

[Healthspan Edge @NotDead_X]

@ilyassahinMD Did the in-person day ever predict who became the better resident?

[Healthspan Edge @NotDead_X]

@yesofficialraja The dream part is the company. Strong social ties raised survival odds about 50 percent.

[Healthspan Edge @NotDead_X]

@chinjung699911 Dancing was linked to the lowest dementia risk of any activity, NEJM 2003.